Abstract

Candida albicans is the most prevalent cause of fungal infections and treatment is further complicated by the formation of drug resistant biofilms, often on the surfaces of implanted medical devices. In recent years, the incidence of fungal infections by other pathogenic Candida species such as C. glabrata, C. parapsilosis and C. tropicalis has increased. Amphiphilic, helical β-peptide structural mimetics of natural antimicrobial α-peptides have been shown to exhibit specific planktonic antifungal and anti-biofilm formation activity against C. albicans in vitro. Here, we demonstrate that β-peptides are also active against clinically isolated and drug resistant strains of C. albicans and against other opportunistic Candida spp. Different Candida species were susceptible to β-peptides to varying degrees, with C. tropicalis being the most and C. glabrata being the least susceptible. β-peptide hydrophobicity directly correlated with antifungal activity against all the Candida clinical strains and species tested. While β-peptides were largely ineffective at disrupting existing Candida biofilms, hydrophobic β-peptides were able to prevent the formation of C. albicans, C. glabrata, C. parapsilosis and C. tropicalis biofilms. The broad-spectrum antifungal activity of β-peptides against planktonic cells and in preventing biofilm formation suggests the promise of this class of molecules as therapeutics.

Highlights

  • Candida albicans is the most common cause of fungal infections in humans, with a high mortality rate of 30%–60% associated with systemic Candida infections [1,2]

  • We demonstrate that a direct correlation exists between β-peptide hydrophobicity, as measured by RP-HPLC retention times, and planktonic antifungal activity against multiple clinical strains of C. albicans and against C. glabrata, C. parapsilosis and C. tropicalis

  • Based on our previous work demonstrating the importance of amphiphilicity and helix stability in β-peptide antifungal activity [29,30,31], all β-peptides used in this study were designed to be globally amphiphilic and contained approximately three residues per helical turn with at least one helix-stabilizing ACHC residue in every turn

Read more

Summary

Introduction

Candida albicans is the most common cause of fungal infections in humans, with a high mortality rate of 30%–60% associated with systemic Candida infections [1,2]. Candidemia, the presence of Candida in the bloodstream, is often associated with the presence of an indwelling medical device such as a central venous catheter, cardiac pacemaker, urinary catheter, or orthopedic implant [1,4,10,11]. While there are drugs that are active against C. albicans, they act on few specific molecular targets, and drug-resistant C. albicans strains lead to reduced efficacy of these drugs in certain cases [15,16]. Many of these drugs exhibit decreased effectiveness against C. albicans biofilms [17,18]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call